NASDAQ:APVOAptevo Therapeutics Stock Price, Forecast & News

Aptevo Therapeutics' stock was trading at $0.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APVO shares have increased by 2,047.6% and is now trading at $9.02. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptevo Therapeutics.

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Aptevo Therapeutics.

Aptevo Therapeutics Inc (NASDAQ:APVO) announced its quarterly earnings data on Wednesday, May, 13th. The biotechnology company reported ($2.84) EPS for the quarter, missing the consensus estimate of ($2.35) by $0.49. Aptevo Therapeutics had a negative return on equity of 224.05% and a negative net margin of 102.54%. View Aptevo Therapeutics' earnings history.

1 analysts have issued 1 year price objectives for Aptevo Therapeutics' stock. Their forecasts range from $3.00 to $18.50. On average, they anticipate Aptevo Therapeutics' share price to reach $10.75 in the next twelve months. This suggests a possible upside of 19.2% from the stock's current price. View analysts' price targets for Aptevo Therapeutics.

News coverage about APVO stock has been trending very negative on Thursday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aptevo Therapeutics earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Aptevo Therapeutics.

Some companies that are related to Aptevo Therapeutics include Theratechnologies (THERF), Savara (SVRA), Trevi Therapeutics (TRVI), OASMIA PHARMACE/ADR (OASM), TFF Pharmaceuticals (TFFP), Catabasis Pharmaceuticals (CATB), Eton Pharmaceuticals (ETON), Axovant Gene Therapies (AXGT), Recro Pharma (REPH), Aptorum Group (APM), Checkpoint Therapeutics (CKPT), KITOV PHARMA LT/S (KTOV), SUMMIT THERAPEU/S (SMMT), Otonomy (OTIC) and Galmed Pharmaceuticals (GLMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Amarin (AMRN), Axsome Therapeutics (AXSM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and Netflix (NFLX).

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APVO stock can currently be purchased for approximately $9.02.

Aptevo Therapeutics has a market capitalization of $29.13 million and generates $32.42 million in revenue each year. The biotechnology company earns $-40,450,000.00 in net income (profit) each year or ($15.27) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.

The official website for Aptevo Therapeutics is www.aptevotherapeutics.com.

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]